A Study Of Senyo Health With Comorbid Substance Use Disorder Treatment In Bipolar Patients

Overview

About this study

The purpose of this study is to examine the effectiveness of a digital IBH platform in improving substance use outcomes, including treatment retention and substance use frequency and severity in patients with BD.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age>=18 years;

  • History of bipolar I disorder, bipolar II disorder, or schizoaffective disorder of the bipolar type

  • Ability to read, write, and understand English

  • Minimum DAST (1+) or audit-C score (3+)

  • Access and willingness to use a mobile device for asynchronous (text) and synchronous (video) engagement with care

  • Eligibility determined by ASAM Assessment

Exclusion Criteria: 

  • Diagnosed personality pathology as the primary presenting concern based on clinical judgment, severe cognitive impairment (e.g., intellectual disability or dementia), or psychosis

  • Inability to actively participate in and learn from psychotherapeutic interaction based on clinical evaluation and clinical judgment

  • Needing a higher level of mental health care as demonstrated by ASAM[36] assessment;

  • Decline to answer suicidality questions

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/01/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Frye

Contact us for the latest status

Contact information:

Ivan Ayala

(507) 538-3987

ayala.ivan@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597425

Mayo Clinic Footer